References
- Sociedad Española de Reumatología. GUIPCAR Guía de Práctica Clínica para el Manejo de la Artritis Reumatoide. 2011
- D’Souza A, Meissner BL, Tang B, et al. Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. Am Health Drug Benefits 2010;3(4):266-73
- Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. Internet 2011 Feb;15(10) Available from: www.journalslibrary.nihr.ac.uk/hta/volume-15/issue-10 [Cited 7 November 2014]
- Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord 2014;15(1):26
- Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm JMCP 2013;19(8):621-30
- Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
- Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
- Societat Catalana de Reumatologia. Teràpia biològica a l’artritis crònica. Document de consens. 2013
- González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology 2014. [Epub ahead of print]
- Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 2013;31(4):559-65
- De la Torre I, Valor L, Nieto JC, et al. Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification. Expert Rev Pharmacoecon Outcomes Res 2013;13(3):407-14
- Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2007;10(5):326-35
- The Association of British Pharmaceutical Industry. The vision for real world data. Harnessing the opportunities in the UK. Demonstrating value with real world data. London: ABPI; White paper: 2011
- Rubio-Terrés C, Ordovás Baines JP, et al. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)]. Farm Hosp Órgano Of Expr Científica Soc Esp Farm Hosp 2007;31(2):78-92
- Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29(1):26-34
- Cannon GW, DuVall SL, Haroldsen CL, et al. Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. J Rheumatol 2014;41(10):1935-43
- Joyce AT, Gandra SR, Fox KM, et al. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. J Med Econ 2014;17(1):1-10
- Huang X, Gu NY, Fox KM, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 2010;26(7):1637-45
- Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31(4):825-35
- Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 2012;15(2):332-9
- Bonafede MMK, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29(3):234-48
- Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2010;67(15):1281-7